Clear Search sequence regions


  • 2 microglobulin (1)
  • 6A1 (3)
  • adeno (1)
  • anti apoptosis (1)
  • apoptosis (7)
  • ATG5 (1)
  • ATG7 (2)
  • beta 2- microglobulin (1)
  • bi 2536 (1)
  • cancer (2)
  • cccp (1)
  • cell cycle (2)
  • COX6A1 (7)
  • EGFR (2)
  • electron transport complex iv (2)
  • eosin (1)
  • gefitinib (14)
  • GOT1 (1)
  • growth factor (1)
  • hematoxylin (1)
  • impairs (1)
  • kinases (2)
  • LC3 (1)
  • liver (5)
  • lung (1)
  • lung neoplasms (1)
  • MAP1LC3 (1)
  • mice (2)
  • non- small cell lung cancer (1)
  • oxygen (1)
  • PLK1 (7)
  • ROS (1)
  • subunit (4)
  • TUBB8 (1)
  • tubulin beta 8 (1)
  • Sizes of these terms reflect their relevance to your search.

    Liver dysfunction is an outstanding dose-limiting toxicity of gefitinib, an EGFR (epidermal growth factor receptor)-tyrosine kinase inhibitor (TKI), in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). We aimed to elucidate the mechanisms underlying gefitinib-induced hepatotoxicity, and provide potentially effective intervention strategy. We discovered that gefitinib could sequentially activate macroautophagy/autophagy and apoptosis in hepatocytes. The inhibition of autophagy alleviated gefitinib-induced apoptosis, whereas the suppression of apoptosis failed to lessen gefitinib-induced autophagy. Moreover, liver-specific Atg7+/- heterozygous mice showed less severe liver injury than vehicle, suggesting that autophagy is involved in the gefitinib-promoted hepatotoxicity. Mechanistically, gefitinib selectively degrades the important anti-apoptosis factor COX6A1 (cytochrome c oxidase subunit 6A1) in the autophagy-lysosome pathway. The gefitinib-induced COX6A1 reduction impairs mitochondrial respiratory chain complex IV (RCC IV) function, which in turn activates apoptosis, hence causing liver injury. Notably, this autophagy-promoted apoptosis is dependent on PLK1 (polo like kinase 1). Both AAV8-mediated Plk1 knockdown and PLK1 inhibitor BI-2536 could mitigate the gefitinib-induced hepatotoxicity in vivo by abrogating the autophagic degradation of the COX6A1 protein. In addition, PLK1 inhibition could not compromise the anti-cancer activity of gefitinib. In conclusion, our findings reveal the gefitinib-hepatotoxicity pathway, wherein autophagy promotes apoptosis through COX6A1 degradation, and highlight pharmacological inhibition of PLK1 as an attractive therapeutic approach toward improving the safety of gefitinib-based cancer therapy.Abbreviations: 3-MA: 3-methyladenine; AAV8: adeno-associated virus serotype 8; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; CCCP: carbonyl cyanide m-chlorophenylhydrazone; CHX: cycloheximide; COX6A1: cytochrome c oxidase subunit 6A1; c-PARP: cleaved poly(ADP-ribose) polymerase; CQ: chloroquine; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; HBSS: Hanks´ balanced salt solution; H&E: hematoxylin and eosin; MAP1LC3/LC3: microtubule associated proteins 1 light chain 3; PLK1: polo like kinase 1; RCC IV: respiratory chain complex IV; ROS: reactive oxygen species; TUBB8: tubulin beta 8 class VIII.

    Citation

    Peihua Luo, Hao Yan, Jiangxia Du, Xueqin Chen, Jinjin Shao, Ying Zhang, Zhifei Xu, Ying Jin, Nengming Lin, Bo Yang, Qiaojun He. PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy. 2021 Oct;17(10):3221-3237

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33315519

    View Full Text